Elbasvir: Difference between revisions

Latest revision as of 03:54, 13 February 2025

Elbasvir[edit]

Elbasvir is an antiviral drug used in the treatment of hepatitis C. It is a direct-acting antiviral (DAA) agent that targets the nonstructural protein 5A (NS5A) of the hepatitis C virus (HCV). Elbasvir is commonly used in combination with other antiviral medications to enhance its efficacy in clearing the virus from the body.

Mechanism of Action[edit]

Elbasvir works by inhibiting the NS5A protein, which is essential for the replication of the hepatitis C virus. By blocking this protein, elbasvir disrupts the viral replication process, thereby reducing the viral load in the patient's body. This action helps in achieving a sustained virologic response (SVR), which is considered a cure for hepatitis C.

Clinical Use[edit]

Elbasvir is primarily used in combination with grazoprevir, another antiviral agent, to treat chronic hepatitis C infection. This combination is effective against multiple genotypes of the virus, particularly genotypes 1 and 4. The treatment regimen and duration depend on the genotype of the virus and the presence of any resistance-associated substitutions (RASs).

Side Effects[edit]

Common side effects of elbasvir include fatigue, headache, nausea, and insomnia. Patients may also experience elevated liver enzymes, which should be monitored during treatment. Serious side effects are rare but can include severe liver problems, especially in patients with advanced liver disease.

Drug Interactions[edit]

Elbasvir can interact with other medications, potentially affecting their efficacy or increasing the risk of adverse effects. It is important to review all medications a patient is taking before starting treatment with elbasvir. Notable interactions include those with certain anticonvulsants, antiretrovirals, and statins.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-{{intro}}
+== Elbasvir ==
-Zepatier is an oral, fixed combination of antiviral agents that is used to treat chronic hepatitis C, genotypes 1 and 4. This combination has been associated with low rate of transient serum enzyme elevations during therapy, but has not been implicated in cases of clinically apparent [[liver injury]] with [[jaundice]].
-{{moa}}
+[[File:Elbasvir.svg|thumb|right|Chemical structure of Elbasvir]]
-Zepatier is the commercial name for a combination of antiviral agents used to treat chronic hepatitis C associated with HCV genotypes 1 and 4. The hepatitis C virus (HCV) encodes several nonstructural (NS) polypeptides that are essential for its replication, NS3/4 that has protease and helicase activities, NS5A that is a membrane bound polypeptide of uncertain purpose and NS5B an HCV specific, RNA-dependent, RNA polymerase. These polypeptides are effective targets for antiviral therapy of hepatitis C. Zepatier is a fixed dose combination of grazoprevir (graz oh’ pre vir) which is a potent HCV NS3/4 protease inhibitor and elbasvir (elb’ as vir) an NS5A inhibitor. In cell culture and in humans infected with HCV, each of these agents has potent activity against HCV, but antiviral resistance arises rapidly with continued exposure. The combination of several direct acting agents with different molecular targets allows for a sustained viral suppression while avoiding antiviral resistance. The combination of these two agents with and without the ribavirin (an antiviral nucleoside analogue with activity against HCV) was shown to be very effective in suppressing HCV replication in patients infected with HCV genotypes 1 and 4, and to result in sustained virological responses and eradication of HCV in more than 95% of patients when given for 12 weeks or more.
-{{fda}}
+'''Elbasvir''' is an [[antiviral drug]] used in the treatment of [[hepatitis C]]. It is a [[direct-acting antiviral]] (DAA) agent that targets the [[nonstructural protein 5A]] (NS5A) of the hepatitis C virus (HCV). Elbasvir is commonly used in combination with other antiviral medications to enhance its efficacy in clearing the virus from the body.
-{{PAGENAME}} was approved for use in the United States in 2016, the third all-oral antiviral combination to receive approval for chronic hepatitis C. It is available as tablets with the fixed dose combination of 100 mg of grazoprevir and 50 mg of elbasvir.
-{{dose}}
+== Mechanism of Action ==
-The recommended dose in adults is 1 tablet daily for 12 weeks. The addition of ribavirin for 12 weeks and prolongation of therapy to 16 weeks is recommended for some groups of HCV infected patients, such as those with previous non-response to antiviral therapy and those with preexisting resistance associated viral variants. Current indications are limited to patients with HCV genotypes 1 and 4. Side effects are uncommon, but are generally mild and can include fatigue, [[headache]] and [[nausea]].
-{{hepatitis c drugs}}
+Elbasvir works by inhibiting the NS5A protein, which is essential for the replication of the hepatitis C virus. By blocking this protein, elbasvir disrupts the viral replication process, thereby reducing the viral load in the patient's body. This action helps in achieving a sustained virologic response (SVR), which is considered a cure for hepatitis C.
-{{coststubd}}
+== Clinical Use ==
+Elbasvir is primarily used in combination with [[grazoprevir]], another antiviral agent, to treat chronic hepatitis C infection. This combination is effective against multiple genotypes of the virus, particularly genotypes 1 and 4. The treatment regimen and duration depend on the genotype of the virus and the presence of any resistance-associated substitutions (RASs).
+== Side Effects ==
+Common side effects of elbasvir include fatigue, headache, nausea, and insomnia. Patients may also experience elevated liver enzymes, which should be monitored during treatment. Serious side effects are rare but can include severe liver problems, especially in patients with advanced liver disease.
+== Drug Interactions ==
+Elbasvir can interact with other medications, potentially affecting their efficacy or increasing the risk of adverse effects. It is important to review all medications a patient is taking before starting treatment with elbasvir. Notable interactions include those with certain [[anticonvulsants]], [[antiretrovirals]], and [[statins]].
+== Related Pages ==
+* [[Hepatitis C]]
+* [[Direct-acting antiviral]]
+* [[NS5A inhibitors]]
+* [[Grazoprevir]]
+[[Category:Antiviral drugs]]
+[[Category:Hepatitis C treatments]]